inborn errors of metabolism in the ED, NICU and PICU

A bedside reference for suspected inborn errors of metabolism in the ED, NICU and PICU: triage, the critical sample, reversing catabolism and the first-pattern differential.

Quick approach

  1. First actions: assess airway, breathing, circulation and neurologic status. Check bedside glucose immediately, establish IV/IO access, and treat shock and seizures. Evaluate and treat possible sepsis in parallel. Call metabolic genetics and PICU early for encephalopathy, rising ammonia, severe acidosis or refractory hypoglycaemia.
  2. Collect a critical sample: if feasible before treatment, draw glucose, blood gas, electrolytes with anion gap, ammonia, lactate, beta-hydroxybutyrate, liver panel and INR. Send plasma amino acids, acylcarnitines and free/total carnitine, plus urine organic acids and ketones.
  3. Reverse catabolism: for severe hypoglycaemia give 10% dextrose 2 mL/kg IV, then a glucose infusion or appropriate feeds. Calculate the actual glucose infusion rate: GIR (mg/kg/min) = dextrose % x rate (mL/hr) / [6 x weight (kg)].
  4. Work the pattern: high ammonia with respiratory alkalosis suggests a urea-cycle disorder; high anion gap with ketosis suggests an organic acidaemia; hypoglycaemia with inappropriately low ketones suggests a fatty-acid oxidation defect or hyperinsulinism; hypoglycaemia with hepatomegaly and lactate suggests hepatic glycogen storage disease

Red flags & when to escalate

Check bedside glucose immediately in any acutely unwell child. Encephalopathy, rising ammonia, severe acidosis or refractory hypoglycaemia: call metabolic genetics and PICU early. Treat shock, seizures and possible sepsis in parallel - in a sick child, treatment takes priority over the critical sample.

Guidelines, books & articles

Article

GeneReviews - Pompe disease (targeted treatment)

GeneReviews, University of Washington

GeneReviews chapter on Pompe disease, covering CRIM status, immune tolerance induction and the targeted treatment of infantile-onset disease.

Open source
Guideline

ACMG - Evidence-based clinical guideline for PAH deficiency

American College of Medical Genetics and Genomics · 2025

Evidence-based recommendations for phenylalanine hydroxylase deficiency, including lifelong treatment when untreated phenylalanine exceeds 360 micromol/L and a treatment target of 360 micromol/L or less.

Open source
Article

GeneReviews - Biotinidase deficiency

GeneReviews, University of Washington · 2024

Diagnosis and treatment of biotinidase deficiency, including free biotin dosing for profound and partial deficiency and the need for hearing and vision assessment.

Open source
Article

GeneReviews - Medium-chain acyl-CoA dehydrogenase deficiency

GeneReviews, University of Washington · 2024

Management of MCAD deficiency, including the acute illness glucose infusion of 1.5 times maintenance or a GIR of 10-12 mg/kg/min and fasting prevention.

Open source
Article

GeneReviews - Maple syrup urine disease

GeneReviews, University of Washington · 2024

Clinical description, diagnosis and management of MSUD, including the inpatient branched-chain amino acid and BCAA-free formula regimen.

Open source
Guideline

RCH Melbourne - Clinical practice guideline: Hypoglycaemia

Royal Children's Hospital Melbourne · 2024

Assessment and management of hypoglycaemia in children, including the critical sample during hypoglycaemia and initial dextrose therapy.

Open source
Guideline

RCH Melbourne - Clinical practice guideline: Metabolic disorders

Royal Children's Hospital Melbourne · 2024

Emergency and ward approach to suspected inborn errors of metabolism, including initial assessment, critical samples and the first pattern-based differential.

Open source
Article

GeneReviews - Tyrosinemia type I

GeneReviews, University of Washington · 2024

Diagnosis and management of tyrosinemia type I, including nitisinone dosing, dietary restriction and the monitoring schedule.

Open source
Guideline

Nationwide Children's Hospital - Neonatal hyperammonemia clinical pathway

Nationwide Children's Hospital · 2024

A neonatal pathway for hyperammonaemia giving example levocarnitine and hydroxocobalamin regimens used in suspected organic acidaemia.

Open source
Guideline

Carbaglu (carglumic acid) prescribing information

European Medicines Agency · 2023

Label dosing for carglumic acid in acute hyperammonaemia due to NAGS deficiency and in organic acidaemias, with renal adjustment guidance.

Open source
Guideline

Forny et al. - MMA and PA management guidelines, first revision

Journal of Inherited Metabolic Disease · 2021

Consensus management guidelines for methylmalonic and propionic acidaemia, covering acute decompensation, carnitine and cobalamin therapy and long-term diet.

Open source
Guideline

FDA - Kuvan (sapropterin) prescribing information

U.S. Food and Drug Administration · 2020

U.S. label starting doses of sapropterin by age and the 5-20 mg/kg/day titration range for BH4-responsive PAH deficiency.

Open source

No sources are linked to this topic yet. Browse the full guidelines and literature list.

Medication doses

Metabolic

Alglucosidase alfa (Lumizyme)

20 mg/kg IV every 2 weeks.

Monitor: Respiratory and motor function, infusion-associated reactions and anti-drug antibodies per the centre protocol.

Metabolic

Arginine HCl IV

Confirmed urea-cycle disorder: the cited label table lists 200 mg/kg for OTC/CPS1 and 600 mg/kg for ASS1/ASL, over 90-120 min, then the same dose over 24 hr.

Monitor: Plasma ammonia, amino acids and electrolytes; follow with the specialist metabolic centre.

Metabolic

BCAA-free amino acid formula

2-3.5 g/kg/day total protein equivalents in the cited inpatient regimen. Select the product, route and energy prescription with the metabolic dietitian.

Monitor: Plasma branched-chain amino acids, glucose, sodium, osmolality and phosphorus.

Metabolic

Biotin

Profound biotinidase deficiency: 5-10 mg PO daily as a fixed daily dose. Partial deficiency: GeneReviews lists 2.5-10 mg PO daily, with practice variation.

Monitor: Serum biotinidase activity, with hearing and vision assessment.

Metabolic

Carglumic acid

Acute NAGS deficiency: 100-250 mg/kg/day divided in 2-4 doses. Acute PA/MMA hyperammonaemia: 150 mg/kg/day if 15 kg or less; 3.3 g/m2/day if over 15 kg, given PO or enteral tube in 2 divided doses, continuing until ammonia is below 50 micromol/L for up to 7 days per label.

Monitor: Plasma ammonia and clinical status.

Metabolic

Cerliponase alfa (Brineura)

Intraventricular every 2 weeks via a surgically implanted reservoir, followed by the labelled intraventricular electrolyte solution: birth to under 6 months 100 mg; 6 months to under 1 year 150 mg; 1 year to under 2 years 200 mg for the first 4 doses then 300 mg; 2 years and older 300 mg.

Monitor: CSF surveillance, device checks, seizure frequency and motor-language scores.

Metabolic

Dextrose 10% (D10)

10% dextrose 2 mL/kg IV for severe hypoglycaemia under the pediatric emergency protocol, followed by a glucose infusion or appropriate feeds. D10 at 4.8 mL/kg/hr delivers 8 mg/kg/min. Calculate the actual GIR and adjust electrolytes and fluid volume for age, cardiac function and neurologic status.

Monitor: Bedside glucose, GIR, electrolytes, osmolality and fluid balance.

Metabolic

Elosulfase alfa (Vimizim)

2 mg/kg IV once weekly.

Monitor: Urinary keratan sulfate, six-minute walk test and respiratory function.

Metabolic

Galsulfase (Naglazyme)

1 mg/kg IV once weekly.

Monitor: Urinary glycosaminoglycans, endurance and joint mobility.

Metabolic

Hydroxocobalamin

Suspected responsive methylmalonic acidaemia: 1 mg IM is a neonatal pathway initial dose. The stable-state responsiveness protocol uses 1 mg IM daily on 3 consecutive days with serial methylmalonate under metabolic supervision.

Monitor: Serial methylmalonate, plasma amino acids and total homocysteine.

Metabolic

Idursulfase (Elaprase)

0.5 mg/kg IV once weekly.

Monitor: Urinary glycosaminoglycans, six-minute walk test, respiratory and cardiac function.

Metabolic

Imiglucerase (Cerezyme)

2.5 units/kg IV three times weekly up to 60 units/kg IV every 2 weeks. Individualize by disease severity and treatment goals.

Monitor: Haemoglobin, platelet count, spleen and liver volume, bone disease and biomarker response.

Metabolic

Isoleucine and valine

20-120 mg/kg/day each, enteral and/or parenteral under metabolic supervision, adjusted to measured amino acids and clinical response.

Monitor: Serial plasma branched-chain amino acids (leucine, isoleucine and valine) and clinical response.

Metabolic

Laronidase (Aldurazyme)

0.58 mg/kg IV once weekly.

Monitor: Urinary glycosaminoglycans, liver and spleen volume, respiratory function and joint mobility.

Metabolic

Levocarnitine (organic acidaemias)

Example neonatal emergency pathway: 50 mg/kg IV or enteral loading, then 100 mg/kg/day IV or enteral, continuous or divided every 6-8 hr. Confirm with the metabolic team.

Monitor: Plasma carnitine, ammonia, blood gas, electrolytes, glucose and urine output.

Metabolic

Levocarnitine (primary carnitine deficiency)

Chronic targeted treatment: 100-200 mg/kg/day PO in 3 doses, titrated to plasma carnitine.

Monitor: Plasma free and total carnitine; cardiac function where cardiomyopathy is suspected.

Metabolic

Nitisinone

Starting dose 0.5 mg/kg/dose PO twice daily. Titrate with the specialist per label, up to 2 mg/kg/day.

Monitor: Succinylacetone, amino acids, AFP, liver imaging and drug levels according to the centre protocol.

Metabolic

Olipudase alfa (Xenpozyme)

For non-CNS manifestations, IV every 2 weeks with stepwise escalation in mg/kg: week 0 0.03, week 2 0.1, weeks 4 and 6 0.3, weeks 8 and 10 0.6, week 12 1, week 14 2, week 16 3. Continue 3 mg/kg IV every 2 weeks after the first 3 mg/kg dose.

Monitor: ALT, AST, spleen and liver volume, lung function and infusion-associated reactions.

Metabolic

Pegvaliase (Palynziq)

Subcutaneous. Induction: 2.5 mg once weekly for 4 weeks. Titration: if tolerated, at least 1 week per step - 2.5 mg twice weekly, 10 mg once weekly, 10 mg twice weekly, 10 mg four times weekly, then 10 mg daily. Maintenance: start 20 mg daily; if control is inadequate after at least 24 continuous weeks consider 40 mg daily; if still inadequate after at least 16 continuous weeks at 40 mg consider 60 mg daily (maximum). Discontinue if the response remains inadequate after 16 continuous weeks at 60 mg daily.

Monitor: Blood phenylalanine at baseline and during treatment; hypersensitivity and anaphylaxis.

Metabolic

Sebelipase alfa (Kanuma)

Rapidly progressive disease presenting in the first 6 months of life: 1 mg/kg IV once weekly, increasing to 3 mg/kg weekly and then 5 mg/kg weekly if the response is suboptimal. Other pediatric patients: 1 mg/kg IV every 2 weeks, increasing to 3 mg/kg every 2 weeks if the response is suboptimal.

Monitor: ALT, AST, lipid profile, liver volume and growth.

Metabolic

Sodium phenylacetate + sodium benzoate IV

Each component: 250 mg/kg if 20 kg or less; 5.5 g/m2 if over 20 kg. Give the loading dose over 90-120 min, then the same amount of each over 24 hr. Dilute in D10 and use central access per label.

Monitor: Ammonia every 1-2 hours early in a severe crisis, mental status, glucose, sodium, potassium and acid-base status.

No medication doses are linked to this topic yet. See the full dose reference.